Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioScience Health Innovations (BHIC) EBITDA (2020 - 2025)

Historic EBITDA for BioScience Health Innovations (BHIC) over the last 6 years, with Q3 2025 value amounting to -$8782.0.

  • BioScience Health Innovations' EBITDA fell 11562.58% to -$8782.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $885677.0, marking a year-over-year increase of 219052.42%. This contributed to the annual value of $87000.0 for FY2024, which is 13459.24% up from last year.
  • According to the latest figures from Q3 2025, BioScience Health Innovations' EBITDA is -$8782.0, which was down 11562.58% from $457704.0 recorded in Q2 2025.
  • BioScience Health Innovations' EBITDA's 5-year high stood at $457704.0 during Q2 2025, with a 5-year trough of -$85262.0 in Q2 2023.
  • Moreover, its 5-year median value for EBITDA was -$12668.0 (2021), whereas its average is $30018.4.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 139217.82% in 2022, then soared by 89953.17% in 2025.
  • BioScience Health Innovations' EBITDA (Quarter) stood at -$14089.0 in 2021, then tumbled by 105.25% to -$28917.0 in 2022, then plummeted by 32.71% to -$38376.0 in 2023, then soared by 125.95% to $9957.0 in 2024, then plummeted by 188.2% to -$8782.0 in 2025.
  • Its last three reported values are -$8782.0 in Q3 2025, $457704.0 for Q2 2025, and $426798.0 during Q1 2025.